Navigation Links
ADVENTRX Appoints Vice President of Manufacturing
Date:4/9/2008

SAN DIEGO, April 9, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it has appointed Jose Hechavarria to the new position of vice president of manufacturing. Mr. Hechavarria will be responsible for leading the company's planned commercial manufacturing operations.

"We are pleased to have recruited Jose to our team," said Evan M. Levine, ADVENTRX chief executive officer. "He brings experience and leadership in the drug manufacturing and quality arena, and we believe his expertise will be especially valuable as we continue to develop the commercial manufacturing processes for both ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion)."

Mr. Hechavarria has over 30 years of experience in the pharmaceutical industry and has overseen all aspects of third-party contract manufacturing. He has held various senior positions at companies including Bristol-Myers Squibb, Dupont Pharmaceuticals, DuPont Merck Pharmaceutical Company as well as the New England Nuclear Corporation. Mr. Hechavarria holds a B.S. in chemical technology from the University of Lowell, an A.S. in nuclear engineering technology from the Wentworth Institute, and has completed post graduate training in parenteral therapeutics agents at the University of Tennessee College of Pharmacy.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the risk that preclinical results are not indicative of the success of subsequent clinical trials and the results of pending clinical trials; the potential for ADVENTRX's product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; other difficulties or delays in developing, testing, manufacturing, marketing and obtaining regulatory approval for ADVENTRX's product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the market potential for ADVENTRX's product candidates and ADVENTRX's ability to compete in those markets; the scope and validity of patent protection for ADVENTRX's product candidates; patent and non-patent exclusivity covering Navelbine(R) and Taxotere(R); and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
4. Eric K. Rowinsky Joins ADVENTRX Board of Directors
5. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
6. ADVENTRX Announces Consolidation of Clinical and Management Positions
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
8. ADVENTRX Appoints Vice President of Commercialization
9. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
10. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
11. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Q ... that it will be a featured presenter at the 5th ... New York City at the Grand ... Corin , Q BioMed Inc. CEO, is scheduled to begin ... cover the company,s business strategy, recent developments and outline milestones ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci ... used in leading laboratories all over the globe. Their cute firefly logo has ... manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. ...
(Date:5/25/2016)... AZ (PRWEB) , ... May 25, 2016 , ... ... Dr. Michael Fitzmaurice recently became double board-certified in surgery and surgery of the ... 2015. Dr. Fitzmaurice is no stranger to going above and beyond in his ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling ... her cruciate ligament in her left knee. Lady’s owner Hannah sought the help of ... board-certified veterinary surgeon, to repair her cruciate ligament and help with the pain of ...
Breaking Biology Technology:
(Date:3/14/2016)... March 14, 2016 http://www.apimages.com ... --> - Renvoi : image disponible via ... --> --> DERMALOG, le ... de nouveaux lecteurs d,empreintes digitales pour l,enregistrement des ... sera utilisé pour produire des cartes d,identité aux ...
(Date:3/10/2016)... -- --> --> ... Access Management Market by Component (Provisioning, Directory Services, Password ... Size, by Deployment, by Vertical, and by Region - ... is estimated to grow from USD 7.20 Billion in ... Compound Annual Growth Rate (CAGR) of 12.2% during the ...
(Date:3/9/2016)... , March 9, 2016 ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):